1 |
Bondeson, J. and Maini, R. 2001. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int. J. Clin. Pract. 55, 211-216.
|
2 |
Bong, K. T. and Lee, H. 2020. Analysis and estimation for market share of biologics based on google trends big data. J. Soc. Korea Ind. Syst. Eng. 43, 14-24.
DOI
|
3 |
Carmona, L., Gomez-Reino, J. J., Rodriguez-Valverde, V., Montero, D., Pascual-Gomez, E., Mola, E. M., Carreno, L., Figueroa, M. and Group, B. 2005. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766-1772.
DOI
|
4 |
Chang, H. C., Bao, Z. Z., Yao, Y., Tse, A., Goyarts, E. C., Madsen, M., Kawasaki, E., Brauer, P. P., Sacchettini, J. C. and Nathenson, S. G. 1994. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc. Natl. Acad. Sci. USA. 91, 11408-11412.
DOI
|
5 |
Chothia, C. and Lesk, A. M. 1987. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917.
DOI
|
6 |
De Kruif, J. and Logtenberg, T. 1996. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271, 7630-7634.
DOI
|
7 |
Han, S. H. and Kim, J. K. 2016. The development of anti-DR4 single-chain Fv (ScFv) antibody fused to Escherichia coli alkaline phosphatase. Kor. J. Microbiol. 52, 10-17.
DOI
|
8 |
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E. and Crea, R. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85, 5879-5883.
DOI
|
9 |
Kalandadze, A., Galleno, M., Foncerrada, L., Strominger, J. L. and Wucherpfennig, K. W. 1996. Expression of recombinant HLA-DR2 molecules replacement of the hydrophobic transmembrane region by a leucine zipper dimerization motif allows the assembly and secretion of soluble DR αβ heterodimers. J. Biol. Chem. 271, 20156-20162.
DOI
|
10 |
Kim, C. H., Han, S. H., Kim, H. M., Han, J. Y., Lim, M. W. and Kim, J. K. 2015. The development of murine recombinant single-chain variable domain fragment (ScFv) specific to acute non-lymphocytic leukemia (ANLL) cell line HL60. Kor. J. Microbiol. 51, 115-125.
DOI
|
11 |
Scott, C. A., Garcia, K. C., Carbone, F. R., Wilson, I. A. and Teyton, L. 1996. Role of chain pairing for the production of functional soluble IA major histocompatibility complex class II molecules. J. Exp. Med. 183, 2087-2095.
DOI
|
12 |
Park, D. W., Kim, E. D., Kim, S. H., Han, J. Y. and Kim, J. K. 2011. The development of imerized Chicken Recombinant Single-chain Fv (ScFv) antibody using Leucine Zipper Motif. Kor. J. Microbiol. 47, 328-334.
|
13 |
Park, K. J., Park, D. W., Kim, C. H., Han, B. K., Park, T. S., Han, J. Y., Lillehoj, H. S. and Kim, J. K. 2005. Development and characterization of a recombinant chicken single-chain Fv antibody detecting Eimeria acervulina sporozoite antigen. Biotechnol. Lett. 27, 289-295.
DOI
|
14 |
Rau, R. 2002. Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis. 61, ii70-ii73.
DOI
|
15 |
Reiter, Y., Brinkmann, U., Jung, S. H., Pastan, I. and Lee, B. 1995. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. Protein Eng. 8, 1323-1331.
DOI
|
16 |
Risley, S., Thomas, M. A. and Bray, V. 2004. Rheumatoid arthritis, new standards of care: nursing implications of infliximab. J. Orthop. Nurs. 8, 41-49.
DOI
|
17 |
Shiraishi, T., Suzuyama, K., Okamoto, H., Mineta, T., Tabuchi, K., Nakayama, K., Shimizu, Y., Tohma, J., Ogihara, T., Naba, H., Mochizuki, H. and Nagata, S. 2004. Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem. Biophys. Res. Commun. 322, 197-202.
DOI
|
18 |
Skerra, A. and Pluckthun, A. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240, 1038-1041.
DOI
|
19 |
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. and Tak, P. P. 2008. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117, 244-279.
DOI
|
20 |
Kim, S.W., Wu, S. and Kim, J. K. 2018. The development of anti-DR4 single-chain Fv (ScFv) antibody fused to Streptavidin. Kor. J. Microbiol. 54, 330-342.
DOI
|
21 |
Landschulz, W. H., Johnson, P. F. and McKnight, S. L. 1988. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240, 1759-1764.
DOI
|
22 |
Li, K., Zettlitz, K. A., Lipianskaya, J., Zhou, Y., Marks, J. D., Mallick, P., Reiter, R. E. and Wu, A. M. 2015. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng. Des. Sel. 28, 307-315
DOI
|
23 |
O'Shea, E. K., Rutkowski, R. and Kim, P. S. 1989. Evidence that the leucine zipper is a coiled coil. Science 243, 538-542.
DOI
|
24 |
Martin, A. C. and Thornton, J. M. 1996. Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. J. Mol. Biol. 263, 800-815.
DOI
|
25 |
Min, W., Kim, J. K., Lillehoj, H. S ., Sohn, E. J., Han, J. Y., Song, K. D. and Lillehoj, E. P. 2001. Characterization of recombinant scFv antibody reactive with an apical antigen of Eimeria acervulina. Biotechnol. Lett. 23, 949-955.
DOI
|
26 |
O'Shea, E. K., Klemm, J. D., Kim, P. S. and Alber, T. 1991. X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science 254, 539-544.
DOI
|
27 |
Pack, P., Kujau, M., Schroeckh, V., Knüpfer, U., Wenderoth, R., Riesenberg, D. and Plückthun, A. 1993. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology 11, 1271-1277.
|
28 |
Pack, P. and Plueckthun, A. 1992. Miniantibodies: use of amphipathic helixes to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31, 1579-1584.
DOI
|
29 |
Vinson, C., Acharya, A. and Taparowsky, E. J. 2006. Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim. Biophys. Acta Bioenerg. Gene Struct. Exp. 1759, 4-12.
|
30 |
Verma, R., Boleti, E. and George, A. 1998. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216, 165-181.
DOI
|
31 |
Zimmermann, J., Voss, H., Schwager, C., Stegemann, J. and Ansorge, W. 1988. Automated Sanger dideoxy sequencing reaction protocol. FEBS Lett. 233, 432-436.
DOI
|
32 |
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S. and Whitlow, M. 1988. Single-chain antigen-binding proteins. Science 242, 423-426.
DOI
|